Thromboembolic risks in patients with COVID-19: major concern to consider in our management

Pan Afr Med J. 2020 Apr 27;35(Suppl 2):10. doi: 10.11604/pamj.2020.35.2.22945. eCollection 2020.

Abstract

COVID-19 pandemic is an emergent cardiovascular risk factor and a major cause of mortality worldwide. Thromboembolism is highly suspected as a leading cause of death in these patients through vascular inflammation caused by SARS COV2. Until now there is no real treatment of COVID-19 and many proposed drugs are under clinical trials. Considering the high incidence of thromboembolic events in critically ill patients with COVID-19, prevention of this disorder should be essential in order to reduce mortality in these patients.

Keywords: COVID-19; Thromboembolism risks; management.

Publication types

  • Letter

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / transmission
  • Humans
  • Incidence
  • Pandemics*
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / transmission
  • SARS-CoV-2
  • Thromboembolism / epidemiology
  • Thromboembolism / etiology
  • Thromboembolism / prevention & control
  • Thromboembolism / therapy*